Early antiretroviral therapy (ART) initiation is currently one of the most popular approaches to reduce transmission of HIV-1. The findings from the HIV Prevention Trials Network (HPTN) 052 have indicated that early ART can markedly reduce the risk of sexual transmission to HIV-negative sexual partners among heterosexual couples. Findings of HIV-1 infection treatment studies also support immediate ART initiation. However, the results of the acquired immunodeficiency syndrome (AIDS) and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) study, which was conducted in a rural area of northern KwaZulu-Natal (South Africa), did not show that there was an impact on HIV incidence based on immediate ART initiation. Recently, risk reduction was also reported in an observational study of patients who initiated ART when compared to non-ART in China. The population-level benefits of early ART remain unproven. In order to achieve the World Health Organization’s (WHO) 90-90-90 goal (90% of the people living with HIV know their HIV status, 90% of the people who know their HIV-positive status are accessing treatment, and 90% of the people receiving treatment have suppressed viral loads) for HIV control and prevention, it is worthwhile to assess the factors impacting and limiting the early ART strategy in China.

China’s National Free Antiretroviral Treatment Program (NFATP) began in 2003 and, by the end of 2015, more than 471,140 patients had received ART. Enormous efforts have been made to increase the capability to treat large numbers of people across China. There was an evolution of national ART guidelines following the WHO...
recommendations\(^1,12\): when the NFATP was implemented in 2003, the threshold for ART initiation was a CD4\(^+\) T cell counts less than 200 cells/\(\mu\)L. In 2008, the NFATP guideline was revised calling for ART initiation among patients with CD4\(^+\) T cell counts below 350 cells/\(\mu\)L; this number was further increased to 500 cells/\(\mu\)L in 2010\(^13,14\). Since 2012, ART has been initiated among all serodiscordant couples regardless of their WHO clinical stage or CD4\(^+\) T cell counts. However, to our knowledge, no studies have comprehensively assessed whether the outcomes associated with early ART initiation are feasible and sustainable under programmatic conditions in China.

The Guangxi Zhuang Autonomous Region (Guangxi) is situated in southwest China bordering Vietnam. Guangxi reported 97,389 (cumulative HIV incidence: 0.2%) cases of AIDS and HIV infections until December 31, 2014, representing 15% of the total number of reported HIV and AIDS cases in China\(^15\). By 2014, heterosexual transmission accounted for 93% of reported HIV infection cases in this region. Research in Guangxi could provide us with reliable information to measure the effect of early ART on the transmission of HIV-1 in China, and thereby assess the feasibility of such an approach in a real-world setting. The aim of this study was to compare the differences in risk reduction in HIV-1 transmission within various populations from programmatic settings, and to analyze the factors affecting the implementation of TasP in China.

**Results**

**General characteristics of study participants.** Overall, 13132 couples were included in which one partner was HIV-1-positive and the other was HIV-1-negative. Based on the guidelines and WHO recommendations\(^13,14\), 1339, 7496 and 4297 couples were included in the late, mid, and early-ART initiation groups, respectively.

Demographic characteristics of the participants enrolled in the different ART groups are summarized in Table 1. There were significant differences between the groups based on sex, age, education, marital status, occupation and route of HIV-1 transmission. A greater proportion of other or unknown route of HIV transmission were in late-ART initiation group.

| Route of HIV transmission | Late-ART Total No. (%) | Mid-ART Total No. (%) | Early-ART Total No. (%) |
|---------------------------|------------------------|-----------------------|------------------------|
| Heterosexual intercourse  | 925 (69.08%)           | 6885 (82.46%)         | 4116 (84.45%)          |
| Other or unknown          | 414 (30.92%)           | 611 (17.54%)          | 181 (15.48%)           |
| Route of HIV transmission | Total                  | 1339 (100%)           | 7496 (100%)            | 4297 (100%)            |

Table 1. Baseline characters of the study participants of late, middle and early ART groups.

Seroconversion rates of late, mid, and early-ART groups. In the late-ART group, 106 HIV transmissions were identified, giving an incidence rate of 8.1 per 100 person-years (95% confidence interval [CI] 6.6–9.6). The rate of transmission in the treated cohort (6.7 per 100 person-years, 95% CI 5.0–8.4) was significantly lower (\(P < 0.05\)) than that in the treatment-naive cohort (11.2 per 100 person-years, 95% CI 8.0–14.5), with an overall 38% reduction in the risk of HIV transmission in the late-ART group (adjusted hazard ratio [AHR] 0.62, 95% CI 0.42–0.94). In the mid-ART group, 276 HIV transmissions were identified, giving an incidence rate of 4.2 per 100 person-years (95% CI 3.7–4.7). The rate of transmission in the treated cohort (3.1 per 100 person-years, 95% CI 2.5–3.6) was significantly lower (\(P < 0.05\)) than that in the treatment-naive cohort (5.9 per 100 person-years, 95% CI 5.0–6.9), with an overall 47% reduction in risk of HIV transmission in the mid-ART group (AHR 0.53, 95% CI 0.41–0.68). In the early-ART group, 65 HIV transmissions were identified, giving an incidence rate of 2.7 per 100 person-years (95% CI 1.4–2.4). The rate of transmission in the treated cohort (1.0 per 100 person-years, 95% CI 0.6–1.4) was significantly lower (\(P < 0.05\)) than that in the treatment-naive cohort (5.3 per 100 person-years, 95% CI 3.6–7.0), with an overall 68% reduction in risk of HIV transmission in the early-ART group (AHR 0.32, 95% CI 0.19–0.54) (Table 2).
Hazard ratios for the association between all partner infections and clinical and demographic factors in the study groups (Intention-to-Treat Analysis).

| Factors                              | HR (95% CI)   | AHR* (95% CI) |
|--------------------------------------|---------------|---------------|
| Early-ART vs. Late-ART               | 0.58 (0.41, 0.81) | 0.55 (0.37, 0.81) |
| Mid-ART vs. Late-ART                 | 0.68 (0.54, 0.85) | 0.61 (0.48, 0.78) |
| Early-ART vs. Mid-ART                | 0.74 (0.56, 0.98) | 0.81 (0.61, 1.08) |
| Baseline CD4⁺ T cell counts (per 100 cells/μL CD4 increment) | 1.01 (0.97, 1.04) | 0.90 (0.86, 0.94) |
| Baseline viral load (per unit log_{10} increment) | 1.42 (1.33, 1.51) | 1.41 (1.33, 1.51) |
| Missed doses in the last month       | 1.63 (1.08, 2.45) | 1.55 (1.03, 2.35) |

Table 2. Comparison of seroconversion rates by treatment status. *Rate is number of seroconversions per 100 person-years. **Non-ART includes pre-treatment groups. *Adjusted for: sex, age, education, marital status, occupation, and route of HIV transmission.

Hazard ratios for the association between all partner infections and clinical and demographic factors in the study groups.

Comparison of seroconversion rates, hazard ratios and attrition rates based on CD4⁺ T cell counts.

In order to determine the relationship between the CD4⁺ T cell counts and HIV transmission, all serodiscordant couples were divided into four groups according to the CD4⁺ T cell counts (0–199 cells/μL, 200–349 cells/μL, 350–499 cells/μL, ≥500 cells/μL). We found that the rate of seroconversions increased with decreased CD4⁺ T cell counts in the non-ART groups. The highest rate of seroconversions was among those in the group with CD4⁺ T cell counts of 0–199 cells/μL (5.4 per 100 person-years, 95% CI 4.0–6.9), and the lowest rate was among those in the group with CD4⁺ T cell counts ≥500 cells/μL. However, the risk reduction in early ART and mid ART groups was not significant. Additionally, increased baseline CD4⁺ T cell counts were associated with lower rates of infections among partners (AHR 0.90, 95% CI 0.86–0.94), while an increased baseline viral load was associated with more frequent partner infections (AHR 1.41, 95% CI 1.33–1.51). Drug compliance (missed doses in the last month) was associated with an increased risk of infections among partners in the treated group (AHR 1.55, 95% CI 1.03–2.35) (Table 3).

Discussion

In the ITT analysis, we noted a 45% lower risk of HIV-1 infection among partners in the early ART group than in the late ART group and a 39% lower risk in the mid ART than in the late ART group. Early ART significantly blocked the HIV transmission in discordant couples in a public health intervention program in China, indicating both personal and public health benefits of this treatment model. The HPTN 052 study provided an absolute number to the prevention benefits of early ART among serodiscordant couples – a reduction in transmission of 96%. A lower level of risk reduction was observed in this study. However, the results of this study were better than those from the large scale clinical trial of ANRS 12249 in South African, which showed that immediate ART initiation did not have an effect on HIV incidence. The Chinese government aims to achieve a significant reduction
| CD4 (cells/μL) | ART/Non-ART | No. | Person-years | Seroconversions | Rate* (95%CI) | HR(95%CI) | AHR † (95%CI) | Attrition (%) |
|---------------|-------------|-----|--------------|----------------|--------------|----------|--------------|--------------|
| 0–199         | Total       | 5024| 10563.66     | 198            | 1.9(1.6, 2.1)|          |              |              |
|               | Non-ART     | 1681| 1011.18      | 55             | 5.4(4.0, 6.9)| 1.0      |              |              |
|               | ART         | 3343| 9554.49      | 143            | 1.5(1.3, 1.7)| 0.44(0.32, 0.61)| 0.47(0.34, 0.65) | 168(5.1) |
| 200–349       | Total       | 3370| 5200.20      | 98             | 1.9(1.5, 2.3)|          |              |              |
|               | Non-ART     | 1719| 1064.48      | 51             | 4.8(3.5, 6.1)| 1.0      |              |              |
|               | ART         | 1651| 4315.72      | 47             | 1.1(0.8, 1.5)| 0.35(0.23, 0.54)| 0.36(0.24, 0.55) | 147(9.6) |
| 350–499       | Total       | 2257| 2543.10      | 79             | 3.1(2.4, 3.8)|          |              |              |
|               | Non-ART     | 1742| 1476.34      | 68             | 4.6(3.5, 5.7)| 1.0      |              |              |
|               | ART         | 515 | 1066.76      | 11             | 1.0(0.4, 1.6)| 0.36(0.19, 0.68)| 0.33(0.17, 0.64) | 52(11.6) |
| ≥500          | Total       | 2198| 2377.93      | 61             | 2.6(1.9, 3.2)|          |              |              |
|               | Non-ART     | 1876| 1876.30      | 56             | 3.0(2.2, 3.8)| 1.0      |              |              |
|               | ART         | 214 | 501.63       | 5              | 1.0(0.1, 1.9)| 0.67(0.27, 1.70)| 0.62(0.24, 1.58) | 25(14.9) |

Table 4. Comparison of seroconversion rates, hazard ratios and attrition rates by CD4+ T cell counts. *Rate is number of seroconversions per 100 person-years. † Adjusted for: sex, age, education, marital status, occupation, and route of HIV transmission.

in HIV incidence and HIV-related mortality by adopting the World Health Organization’s 90-90-90 policy. For many years, ART was delayed until a patient’s CD4 count fell below 200 cells/μL in China, which led to the frequent occurrence of opportunistic infections. To our knowledge, this is the first large observational study in China assessing the outcomes of early ART over the past ten years. The results of this study could be extrapolated, suggesting that the expansion of the use of early ART could reduce the spread of HIV in China.

It is worth noting that, no significant reduction in transmission risk was observed between the early-ART and mid-ART group in this study. Nonetheless, the study provides numerous lessons learnt about the challenges of achieving treatment as prevention at a population level. In particular, this study demonstrates that the treatment was effective in a CD4 threshold of 200–350 cells/μL, with the impact reducing with increased CD4 threshold of 350–500 cells/μL or greater. Prevention of HIV transmission with early ART was feasible on a national and regional scale; however, the full benefits of this strategy will probably need universal access to very early ART and excellent adherence to treatment. Drug compliance (missed doses in the last month) (AHR 1.55, 95% CI 1.03–2.35) and increased baseline viral load (per unit log10 increment) (AHR 1.41, 95% CI 1.33–1.51) were associated with an increased risk of infections among partners in the treatment. In this study, the time of ART treatment was stratified by CD4+ T cell counts, therefore the early, mid, and late treatment groups had significant differences in their CD4+ T cell counts. Lower CD4+ T cell counts account for immuno-deficiency and uncontrolled viral loads, and may also contribute to increased HIV infection in the late group compared to the other groups. After controlling for viral load, the decreased risk in early-ART and mid-ART groups increased, however this was not significant (AHR 0.79, 95% CI, 0.61–1.03, ? = 0.09). These findings highlight the challenges of attaining long-term viral suppression in HIV-infected individuals who will be taking life-long ART, so as to reduce risk of infection and prevent spread of AIDS. Rapid expansion of ART without assuring viral suppression can undermine ART effectiveness and contribute to negative public health outcomes, such as the emergence of HIV drug resistance. Development of inexpensive point of care tests for viral load monitoring could permit real-time viral load testing that might allow targeted ART provision to those who have higher CD4+ T cell counts and high viral loads. This might assist in addressing the known relationship between viral load to HIV-1 transmission risk.

The rates of HIV transmission through heterosexual intercourse were 69%, 91%, and 95% in the late, mid, and early groups respectively, thus controlling for the route of transmission for 45% and 39% risk reductions was also important. China has come a long way in the provision free ART, coupled with substantially escalated efforts and scaling up of many crucial services in the past ten years. In the late-ART group, many patients (31%) were not significant (AHR 0.79, 95% CI, 0.61–1.03, ? = 0.09). These findings highlight the challenges of attaining long-term viral suppression in HIV-infected individuals who will be taking life-long ART, so as to reduce risk of infection and prevent spread of AIDS. Rapid expansion of ART without assuring viral suppression can undermine ART effectiveness and contribute to negative public health outcomes, such as the emergence of HIV drug resistance. Development of inexpensive point of care tests for viral load monitoring could permit real-time viral load testing that might allow targeted ART provision to those who have higher CD4+ T cell counts and high viral loads. This might assist in addressing the known relationship between viral load to HIV-1 transmission risk.

The rates of HIV transmission through heterosexual intercourse were 69%, 91%, and 95% in the late, mid, and early groups respectively, thus controlling for the route of transmission for 45% and 39% risk reductions was also important. China has come a long way in the provision free ART, coupled with substantially escalated efforts and scaling up of many crucial services in the past ten years. In the late-ART group, many patients (31%) were not significant (AHR 0.79, 95% CI, 0.61–1.03, ? = 0.09). These findings highlight the challenges of attaining long-term viral suppression in HIV-infected individuals who will be taking life-long ART, so as to reduce risk of infection and prevent spread of AIDS. Rapid expansion of ART without assuring viral suppression can undermine ART effectiveness and contribute to negative public health outcomes, such as the emergence of HIV drug resistance. Development of inexpensive point of care tests for viral load monitoring could permit real-time viral load testing that might allow targeted ART provision to those who have higher CD4+ T cell counts and high viral loads. This might assist in addressing the known relationship between viral load to HIV-1 transmission risk.

A key element in the serodiscordant couples’ prevention strategy is the use of early ART. However, translation of research findings into public health practice represents an exciting prospect which comes with many challenges. First, not all HIV-infected individuals can be located in time, especially people with acute and early infection who are most contagious in limited healthcare resources. Second, in China, more than half of HIV-1 infected people live in rural areas. HIV-1 infection is difficult to identify and treat immediately if the infection is not in its advanced stage in the vast majority of rural areas. Socially, those most likely to transmit HIV are often not in its advanced stage in the vast majority of rural areas. First, not all HIV-infected individuals can be located in time, especially people with acute and early infection who are most contagious in limited healthcare resources. Second, in China, more than half of HIV-1 infected people live in rural areas. HIV-1 infection is difficult to identify and treat immediately if the infection is not in its advanced stage in the vast majority of rural areas. Socially, those most likely to transmit HIV are often not in its advanced stage in the vast majority of rural areas.

One notable difference is the seroconversion rate of IDUs in the world in this time. In the mid and early groups, sexual transmission was the major route of transmission. These factors, along with early ART, have all contributed to the risk reductions. China assessing the outcomes of early ART over the past ten years. The results of this study could be extrapolated, suggesting that the expansion of the use of early ART could reduce the spread of HIV in China. It is worth noting that, no significant reduction in transmission risk was observed between the early-ART and mid-ART group in this study. Nonetheless, the study provides numerous lessons learnt about the challenges of achieving treatment as prevention at a population level. In particular, this study demonstrates that the treatment was effective in a CD4 threshold of 200–350 cells/μL, with the impact reducing with increased CD4 threshold of 350–500 cells/μL or greater. Prevention of HIV transmission with early ART was feasible on a national and regional scale; however, the full benefits of this strategy will probably need universal access to very early ART and excellent adherence to treatment. Drug compliance (missed doses in the last month) (AHR 1.55, 95% CI 1.03–2.35) and increased baseline viral load (per unit log10 increment) (AHR 1.41, 95% CI 1.33–1.51) were associated with an increased risk of infections among partners in the treatment. In this study, the time of ART treatment was stratified by CD4+ T cell counts, therefore the early, mid, and late treatment groups had significant differences in their CD4+ T cell counts. Lower CD4+ T cell counts account for immuno-deficiency and uncontrolled viral loads, and may also contribute to increased HIV infection in the late group compared to the other groups. After controlling for viral load, the decreased risk in early-ART and mid-ART groups increased, however this was not significant (AHR 0.79, 95% CI, 0.61–1.03, ? = 0.09). These findings highlight the challenges of attaining long-term viral suppression in HIV-infected individuals who will be taking life-long ART, so as to reduce risk of infection and prevent spread of AIDS. Rapid expansion of ART without assuring viral suppression can undermine ART effectiveness and contribute to negative public health outcomes, such as the emergence of HIV drug resistance. Development of inexpensive point of care tests for viral load monitoring could permit real-time viral load testing that might allow targeted ART provision to those who have higher CD4+ T cell counts and high viral loads. This might assist in addressing the known relationship between viral load to HIV-1 transmission risk.
The highest attrition rates (14.9%, 95% CI, 9.0–20.7) were found among individuals with CD4 ≥ 500 cells/μL. This finding suggests that education on adherence must be strengthened to control the higher rate of ART attrition when CD4+ T cell counts are above 500 cells/μL. The 2013 WHO guidelines for ART recommended initiation at CD4+ T cell counts 500 cells/μL and immediate ART initiation among specific groups including serodiscordant couples. Several countries have already revised the CD4 threshold to above 500 cells/μL. Recently, another study based on a large ART treatment database in Guangxi showed that HIV infected patients with high CD4+ T cell counts at the time of ART initiation may be at greater risk of treatment attrition. By the end of 2015, a total of 41013 patients terminated ART in China, accounting for 8.7% of the total number of NFATP within China. Attrition, even with the degree observed in our study, can affect further transmission of HIV and HIV resistant drug variants, and lead to premature morbidity and mortality. Therefore, effective strategies to promote retention in HIV care programs are needed when early ART programs are implemented on a large scale in resource-limited settings.

Although HIV transmission from patients with AIDS appears to be most common, the results from this and other studies emphasize that HIV-1 can be transmitted from infected persons who are asymptomatic or minimally symptomatic and who have high CD4+ T cell counts. Most HIV-1-positive patients CD4+ T cell counts raise the longer they are on ART. If the CD4+ T cell count remains low, the transmission of HIV-1 will continue.

Our study had several limitations. First, the number of seroconversions in the early-ART group was small, and this could lead to insufficient statistical power for the adjusted analyses. Second, the follow-up time on ART in this study was short, relative to the lifetime duration of ART. As such, the long-term protection efficacy of ART needs to be confirmed in additional studies: future studies need statistical power to measure the long-term protection against transmission overtime, including sufficient number of seroconversions over the observational period. It is also essential to obtain reliable information about the comparative long-term transmission benefits and behavioral risks associated with ART, particularly ART initiated at higher CD4+ T cell count levels.

Our results strongly indicate feasibility of early ART in the prevention of HIV transmission in serodiscordant couples within programmatic settings. This study also indicated that higher viral loads and poor adherence can enhance the risk for HIV transmission. Our study provides new evidence for the effectiveness of the public health TasP strategy. These findings support the implementation of the WHO’s 90-90-90 strategy in developing countries.

Methods

Study design and study population. This retrospective observational cohort study was conducted primarily in Guangxi, and used data collected from January 1, 2003 to December 31, 2014. Individuals were included if they were: aged 18 years or older; sexually active; HIV-negative; married to or cohabiting with a HIV-positive partner; willingness to participate in this study and provide written informed consent.

Study Definitions. ART was initiated among participants with CD4+ T cell counts less than 200 cells/μL (late-ART group), 350 cells/μL (mid-ART group), and 500 cells/μL (early-ART group) according to the evolution of national guidelines and WHO recommendations. In the late-ART group individuals were also recommended to initiation ART regardless of WHO clinical stage. In the early-ART group, ART was expected to be initiated among all index-partners regardless of WHO clinical stage or CD4+ T cell counts. Attrition was investigated in the 6-month cohort and was defined as the proportion of patients in each group no longer receiving ART at their initiating facility.

Data Collection and Variables. At baseline and follow-up visits, both HIV-positive and HIV-negative spouses were asked about their demographic characteristics including gender, age, education, marital status, occupation, and the most probable route of infection. The local CDC followed up on these couples every 6 months: HIV-positive individuals were followed up for repeated CD4+ T cell counts and clinical evaluation; HIV-negative partners were tested for HIV seroconversion.

Statistical analysis. During the follow-up, the treatment effectiveness of ART in HIV-1 acquisition among HIV-negative partners was assessed using the extended Cox regression model with treatment status as a time-varying covariate. Intention-to-treat (ITT) analysis was used in comparing the risk differences between the groups (early-ART versus late-ART, early-ART versus mid-ART, and mid-ART versus late-ART). We calculated the relative hazard of primary outcomes for treatment by subgroups (baseline CD4+ T cell counts, sex, age, and duration of follow-up of the index case). Couples who were lost to follow-up (including couples who separated during the follow-up period) or in which either partner died, were right-censored on the date of last contact. A two-sided P-value of 0.05 or less was considered significant. The epidemiology and treatment databases were double-checked in both a relational database designed in SQL Server 2008 and in SAS 9.4. Statistical analyses were conducted using SAS 9.4.

Ethical approvals. All subjects provided written informed consent to participate in this study. This study and all methods were approved by the institutional review board (IRB) of the National Center for AIDS/STD Control and Prevention, China CDC, and Guangxi Center for Disease Control and Prevention. All methods were performed in accordance with the relevant guidelines and regulations.

Data availability statements. All data generated or analysed during this study are included in this published article.
References
1. Jia, Z. et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003–11): a national observational cohort study. Lancet 382, 1199–1203, https://doi.org/10.1016/S0140-6736(12)61898-4 (2013).
2. Jiwatram-Negron, T. & El-Bassel, N. Systematic review of couple-based HIV intervention and prevention studies: advantages, gaps, and future directions. AIDS and behavior 18, 1864–1887, https://doi.org/10.1007/s10461-014-0827-7 (2014).
3. Muesing, K. E. & Cohen, M. S. Advances in HIV prevention for serodiscordant couples. Current HIV/AIDS reports 11, 434–446, https://doi.org/10.1007/s11994-014-0225-9 (2014).
4. Knight, R., Small, W., Thomson, K., Gilbert, M. & Shoveller, J. Implementation challenges and opportunities for HIV Treatment as Prevention (TasP) among young men in Vancouver, Canada: a qualitative study. BMC public health 16, 262, https://doi.org/10.1186/s12889-016-2943-y (2016).
5. Iwuji, C. C. et al. Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster Randomised Trial. PLoS medicine 13, e1002107, https://doi.org/10.1371/journal.pmed.1002107 (2016).
6. Cohen, M. S. et al. Prevention of HIV-1 infection with early antiretroviral therapy. The New England journal of medicine 365, 493–503, https://doi.org/10.1056/NEJMoa1105243 (2011).
7. Cohen, M. S. et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. The New England journal of medicine 357, 830–839, https://doi.org/10.1056/NEJMoa1600993 (2016).
8. Collaboration, H.-C. et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Annals of internal medicine 154, 509–515, https://doi.org/10.7326/0003-4819-154-8-201104190-00001 (2011).
9. Writing Committee for the C. C. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Archives of internal medicine 171, 1560–1569, https://doi.org/10.1001/archinternmed.2011.401 (2011).
10. HPTN Responds to Results from ANRS 12249 TasP Study Presented at AIDS 2016. Available: https://www.hptn.org/news-and-events/press-releases/hptn-responds-to-results-from-ans-12249-tasp-study-presented-at (cited June 2017).
11. NCAIDS, NCSTD, and China CDC. Update on the AIDS/STD epidemic in China and main response in control and prevention in December, 2015. Chin J AIDS STD 2016.
12. Ren, L. et al. Prognosis of HIV Patients Receiving Antiretroviral Therapy According to CD4 Counts: A Long-term Follow-up study in Yunnan, China. Scientific reports 7, 9595, https://doi.org/10.1038/s41598-017-10105-7 (2017).
13. Liao, L. et al. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China. AIDS 27, 1815–1824, https://doi.org/10.1097/QAD.0b013e328361931 (2013).
14. Zhang, F. et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. The Lancet. Infectious diseases 11, 516–524, https://doi.org/10.1016/S1473-3099(11)70097-4 (2011).
15. Guangxi Public Health Department. Annual report on provincial AIDS/STD in 2014. Guangxi, China: Guangxi Public Health Department, 2015.
16. Quinn, T. C. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. The New England journal of medicine 342, 921–929, https://doi.org/10.1056/NEJM200003163421303 (2000).
17. Liu, P. et al. Polymorphisms and Mutual Covariation Associated with Death in a Prospective Cohort of HIV/AIDS Patients Receiving Long-Term ART in China. PLoS one 12, e0170139, https://doi.org/10.1371/journal.pone.0170139 (2017).
18. Xing, H. et al. Reductions in virologic failure and drug resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens, 2003–12. The journal of antimicrobial chemotherapy 70, 2097–2103, https://doi.org/10.1093/jac/dkv078 (2015).
19. Mathers, B. M. et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372, 1733–1745, https://doi.org/10.1016/S0140-6736(08)61311-2 (2008).
20. Ma, Y. et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 50, 264–271, https://doi.org/10.1086/649215 (2010).
21. Wang, J. et al. Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China. Scientific reports 5, 14823, https://doi.org/10.1038/srep14823 (2015).
22. Cohen, M. S. et al. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet 382, 1515–1524, https://doi.org/10.1016/S0140-6736(13)61998-4 (2013).
23. WHO, UNICEF and UNAIDS. Global update on HIV treatment 2013: results, impact and opportunities.Geneva: World Health Organization; 2013 (http://www.who.int/hiv/pub/progresreports/update2013/en/ accessed 25 August 2015).
24. Tang, Z. et al. Effects of high CD4 cell counts on death and attrition among Chinese HIV-infected antiretroviral treatment: an observational cohort study. Scientific reports 7, 3129, https://doi.org/10.1038/s41598-017-03384-7 (2017).
25. Zhu, H. et al. Attrition among human immunodeficiency virus (HIV)-infected patients initiating antiretroviral therapy in China, 2003-2010. Plos one 7, e39414, https://doi.org/10.1371/journal.pone.0039414 (2012).
26. Donnell, D. et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375, 2092–2098, https://doi.org/10.1016/S0140-6736(10)60731-2 (2010).
27. Powers, K. A., Poole, C., Pettifor, A. E. & Cohen, M. S. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. The Lancet. Infectious diseases 8, 553–563, https://doi.org/10.1016/S1473-3099(08)70156-7 (2008).
28. Wawer, M. J. et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. The journal of infectious diseases 191, 1403–1409, https://doi.org/10.1086/429411 (2005).

Acknowledgements
We thank the patients and doctors throughout Guangxi for their consent and support for the study. We are grateful to the study participants and their communities, for their contributions to the research. This study was supported by grants from the National Natural Science Foundation of China (81502862, 81360442, 81460510), Guangxi Science and Technology Bureau (AB16380213), Guangxi Bagui Honor Scholars, Ministry of Science and Technology of China (2012ZX10001-002), Chinese State Key Laboratory of Infectious Disease Development Grant, and the International Development Research Center of Canada (grant #104519-010).

Author Contributions
Conceptualization: P.L., Z.T., Y.R. and Y.S.; Data curation: P.L., Z.T., H.C., X.Y., G.L., Q.Z., S.L., Y.F., Z.S. and Y.C.; Formal analysis: P.L. and X.Y.; Funding acquisition: Z.T., Y.R. and Y.S.; Investigation: Z.T., G.L., Q.Z. and X.Y.; Methodology: P.L. and Y.S.; Project administration: P.L., Y.S., H.X. and Y.R.; Software: P.L.; Supervision: Y.Y., L.L. and Y.R.; Validation: X.Y., S.L., Z.S. and Y.C.; Writing ± original draft: P.L. and Y.Y.; Writing ± review & editing: P.L., Y.Y., Y.S. and Y.R.
Additional Information

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018